Drugs in the Pipeline, News FDA Grants Fast Track Designation to Orismilast for Atopic Dermatitis Publish Date November 4, 2021 The FDA's Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
Drugs in the Pipeline, News Rilzabrutinib Fails in Phase 3 Pemphigus Trial Publish Date September 9, 2021 Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.